Objective: To analyze the clinical characteristics of AIDS-related non-Hodgkin lymphoma (ARL) and review relative literature for the diagnosis and treatment of ARL.
Method: The clinical data of ARL patients admitted to Peking Union Medical College Hospital from April 2009 to April 2011 were retrospectively analyzed.
Results: Five male ARL patients aged 32 to 65 years old were included in this retrospective study. Among them, two patients were found to be HIV-positive for the first time, three were on regular highly active anti-retroviral therapy (HAART) for 7 - 8 months before the emergence of lymphoma-related symptoms. CD(4)(+) T cell count was (69 - 232) × 10(6)/L at presentation. Two patients firstly presented with sore throat and throat ulcer, one with cervical nodules, one with pelvic mass, one with fever and edema in right thigh. Through pathological analysis, four patients had B cell-originated lymphoma, with one Burkitt lymphoma and three diffuse large B cell lymphomas; one patient had T-cell lymphoma. Four patients were treated with chemotherapy, with one complete remission, one relapse, one non-response, and one death. One patient had radiotherapy only and had progressed disease. Bone marrow suppression and gastrointestinal disturbance were the main adverse effects of chemotherapy.
Conclusions: Lymphoma should be considered in any HIV-infected patients presented with unexplainable adenopathy, recurrent sore throat or throat ulcer, or fever of unknown origin. Biopsy should be rigorously carried out. Appropriate chemotherapy, together with HAART, may improve the prognosis greatly.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Extra-Cavitary Primary Effusion Lymphoma in a Patient Co-infected With HIV-1 and HIV-2: A Case Review.
Cureus
December 2024
Infectious Diseases, Hospital Garcia de Orta, Lisbon, PRT.
Extra-cavitary primary effusion lymphoma (PEL), often associated with human herpes virus 8 (HHV8) infection, represents a rare and aggressive form of non-Hodgkin lymphoma, which is predominantly found in individuals with severe immunosuppression. As an acquired immunodeficiency syndrome (AIDS)-associated lymphoma, PEL typically manifests in the context of advanced human immunodeficiency virus (HIV) infection, requiring tailored therapeutic approaches to manage both the lymphoma and underlying immunodeficiency. A 53-year-old male patient from Cape Verde presented with a three-day history of fever, night sweats, right iliac fossa pain, hematochezia, and an unintentional weight loss of five kilograms over the previous two months.
View Article and Find Full Text PDFSurvival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China.
Sci Rep
December 2024
Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.
Article Synopsis
- Combination antiretroviral therapy (ART) has significantly improved the treatment outcomes for patients with HIV-associated non-Hodgkin lymphoma, specifically Burkitt lymphoma and diffuse large B-cell lymphoma, based on a study of 127 patients treated over 17 years.
- The study found that DA-EPOCH ± R was the most common therapy for HIV-BL, while CHOP± R was used for HIV-DLBCL, with complete response rates of 36% and 44%, respectively.
- Despite these advancements, challenges remain in treating HIV-related lymphomas in China due to low rates of pre-diagnosis ART, high patient morbidity, and late-stage diagnoses.
Promising immunotherapeutic approaches for primary effusion lymphoma.
Explor Target Antitumor Ther
June 2024
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
Article Synopsis
- Primary effusion lymphoma (PEL) is a large B-cell cancer that typically presents with fluid build-up in body cavities, primarily affecting people with AIDS and linked to HHV8/KSHV infection.
- Current treatments like combination antiretroviral therapy (cART) extend survival for HIV/AIDS patients, but PEL has a poor prognosis and responds poorly to standard chemotherapy regimens like CHOP.
- There is an urgent need for new treatment strategies; recent discussions focus on emerging immunotherapy options that could improve clinical outcomes for PEL patients.
Complete response to front-line therapies is associated with long-term survival in HIV-related lymphomas in Taiwan.
J Microbiol Immunol Infect
June 2024
Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan.
Background: The prognosis for people living with HIV (PLWH) who develop lymphomas has been greatly improved by combination antiretroviral therapy (cART) and anti-CD20 monoclonal antibodies. However, real-world clinical data on this patient group in Asia are limited.
Methods: Treatment outcomes were retrospectively examined for 104 PLWH with lymphomas between 2000 and 2019.
Expression and prognostic significance of the PD-1/PD-L1 pathway in AIDS-related non-Hodgkin lymphoma.
Cancer Med
April 2024
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Article Synopsis
- The study focuses on how immune tolerance and evasion are linked to virus-driven cancers, especially in AIDS-related non-Hodgkin lymphoma (AR-NHL) influenced by Epstein-Barr virus (EBV).
- It analyzed the presence and significance of PD-1 and its ligands (PD-L1 and PD-L2) in a cohort of 58 AR-NHL patients, finding a 56.9% prevalence of EBV and a notable increase in PD-1-related markers in malignant cells.
- Results showed that patients positive for both EBV and PD-1 or PD-L1 had significantly lower survival rates, highlighting the role of PD-1 in immune evasion and underscoring its potential as a target
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!